

Analyte	Parameter (unit)	Racemic Ketamine 30 mg IN, Day 1							
		N	Mean	SD	Min	Median	Max	Geometric Mean	Geometric CV%
Ketamine	AUC ₀₋₄ (h*ng/mL)	12	130.66	42.73	71.83	119.16	203.62	124.65	32.71
	AUC _{0-inf} (h*ng/mL)	12	141.5	43.57	86.31	131.74	215.22	135.75	30.5
	C _{max} (ng/mL)	12	42.79	15.82	17.86	40.24	82.05	40.26	38.32
	Cl/F(L/h)	12	229.9	65.85	139.39	227.72	347.6	220.99	30.5
	V _d /F(L)	12	1346.52	362.2	619.69	1381.46	2066.45	1296.83	30.64
Analyte	Parameter (unit)	N	Mean	SD	CV	Min	Median	Max	
Ketamine	t _{1/2} (h)	12	4.37	1.85	42.4	-	2.88	3.43	7.91
	λ _z (/h)	12	0.1808	0.0582	32.1747	-	0.0876	0.2028	0.2403
Analyte	Parameter (unit)	N	Min	Max	Median	Q1	Q3		
Ketamine	T _{max} (h)	12	-	0.453	1.069	0.507	0.463	0.798	-

FIG. 1A

Analyte	Parameter (unit)	Racemic Ketamine 75 mg IN, Day 1							
		N	Mean	SD	Min	Median	Max	Geometric Mean	Geometric CV%
Ketamine	AUC ₀₋₁ (h*ng/mL)	12	353.64	71.97	244.27	343.48	484.06	346.89	20.82
	AUC _{0-inf} (h*ng/mL)	12	371	74.16	256.48	356.49	508.38	364.17	20.46
	C _{max} (ng/mL)	12	89.88	24.96	42.18	95.24	133	86.31	31.8
	Cl/F(L/h)	12	209.88	43.04	147.53	210.44	292.43	205.95	20.46
	V _d /F(L)	12	1949.57	503.34	1276.59	1992.01	2856.06	1890.12	26.58
Analyte	Parameter (unit)	N	Mean	SD	CV		Min	Median	Max
Ketamine	t _{1/2} (h)	12	6.39	0.67	10.53	-	5.61	6.32	7.93
	λ _c (/h)	12	0.1095	0.0108	9.8883	-	0.0874	0.1098	0.1235
Analyte	Parameter (unit)	N		Min	Max	Median	Q1	Q3	
Ketamine	T _{max} (h)	12	-	0.482	1.57	0.805	0.671	0.819	-

FIG. 1B

Analyte	Parameter (unit)	Racemic Ketamine 90 mg IN, Day 1							
		N	Mean	SD	Min	Median	Max	Geometric Mean	Geometric CV%
Ketamine	AUC ₀₋₄ (h*ng/mL)	12	431.26	132.44	225.05	438.76	658.96	411.49	33.72
	AUC _{0-inf} (h*ng/mL)	11	434.54	127.81	232.94	461.26	661.41	416.34	32.28
	C _{max} (ng/mL)	12	115.01	44.24	68.89	101.45	207.05	107.75	38.75
	Cl/F(L/h)	11	226.53	75.99	136.07	195.12	386.37	216.17	32.28
	V _d /F(L)	11	1874.63	703.79	915.59	1690.2	3253.33	1762.02	38.2
Analyte	Parameter (unit)	N	Mean	SD	CV		Min	Median	Max
Ketamine	t _{1/2} (h)	11	6.06	2.01	33.17	-	2.5	6.97	8.1
	λ _z (/h)	11	0.1352	0.0715	52.9232	-	0.0856	0.0994	0.2768
Analyte	Parameter (unit)	N		Min	Max	Median	Q1	Q3	
Ketamine	T _{max} (h)	12	-	0.456	1.058	0.798	0.483	1.031	-

FIG. 1C

Analyte	Parameter (unit)	Racemic Ketamine 30 mg IN, Day 4							
		N	Mean	SD	Min	Median	Max	Geometric Mean	Geometric CV%
Ketamine	AUC ₀₋₁ (h*ng/mL)	11	142.01	72.64	81.97	119.54	334.85	129.99	43.16
	AUC _{0-inf} (h*ng/mL)	11	153.27	74.31	93.28	130.67	349.73	141.38	41.25
	C _{max} (ng/mL)	11	43.46	25.07	22.46	31.82	97.72	38.72	49.77
	Cl/F(L/h)	11	225.92	74.91	85.78	229.58	321.62	212.2	41.25
	V _d /F(L)	11	1136.99	336.69	672.56	1161.74	1672.84	1089.84	31.85
Analyte	Parameter (unit)	N	Mean	SD	CV		Min	Median	Max
Ketamine	t _{1/2} (h)	11	3.66	1.01	27.61	-	2.65	3.51	6.33
	λ _z (/h)	11	0.1994	0.0421	21.1283	-	0.1096	0.1976	0.2617
Analyte	Parameter (unit)	N		Min	Max	Median	Q1	Q3	
Ketamine	T _{max} (h)	11	-	0.457	1.074	0.796	0.467	1.031	-

FIG. 2A

Analyte	Parameter (unit)	Racemic Ketamine 75 mg IN, Day 4							
		N	Mean	SD	Min	Median	Max	Geometric Mean	Geometric CV%
Ketamine	AUC _{0-t} (h*ng/mL)	11	360.79	66.68	273.63	352.27	491.87	355.35	18.39
	AUC _{0-inf} (h*ng/mL)	11	377.91	68.35	287.79	364.18	516.74	372.47	17.9
	C _{max} (ng/mL)	11	94.07	25.58	50.96	98.92	131.82	90.62	30.17
	Cl/F(L/h)	11	204.23	35.66	145.14	205.94	260.6	201.36	17.9
	V _d /F(L)	11	1831.88	490.58	1310.56	1753.1	2929.72	1778.71	25.28
Analyte	Parameter (unit)	N	Mean	SD	CV	Min	Median	Max	
Ketamine	t _{1/2} (h)	11	6.18	0.95	15.44	-	5.04	6.16	8.65
	λ _z (/h)	11	0.1142	0.0153	13.3946	-	0.0801	0.1126	0.1376
Analyte	Parameter (unit)	N	Min	Max	Median	Q1	Q3		
Ketamine	T _{max} (h)	11	-	0.454	1.048	0.799	0.463	0.826	-

FIG. 2B

Analyte	Parameter (unit)	Racemic Ketamine 90 mg IN, Day 4							
		N	Mean	SD	Min	Median	Max	Geometric Mean	Geometric CV%
Ketamine	AUC ₀₋₄ (h*ng/mL)	12	362.86	82.8	224.97	365.98	510.78	353.81	24.22
	AUC _{0-inf} (h*ng/mL)	12	382.93	92.55	234.97	383.21	554.33	372.36	25.47
	C _{max} (ng/mL)	12	96.3	22.41	66.77	93.57	150.05	94.11	22.4
	Cl/F(L/h)	12	248.93	64.9	162.36	234.86	383.03	241.7	25.47
	V _d /F(L)	12	2052.17	726.37	1148.75	1858.59	3755.69	1943.63	35.31
Analyte	Parameter (unit)	N	Mean	SD	CV	Min	Median	Max	
Ketamine	t _{1/2} (h)	12	5.96	1.94	32.62	-	2.45	6.66	8.1
	λ _z (/h)	12	0.1362	0.0698	51.1992	-	0.0831	0.1041	0.2768
Analyte	Parameter (unit)	N		Min	Max	Median	Q1	Q3	
Ketamine	T _{max} (h)	12	-	0.456	1.533	0.803	0.468	0.93	-

FIG. 2C

Analyte	Parameter (unit)	Racemic Ketamine 30 mg IN, Day 8							
		N	Mean	SD	Min	Median	Max	Geometric Mean	Geometric CV%
Ketamine	AUC ₀₋₁ (h*ng/mL)	10	150.29	55.01	101.03	145.96	296.68	143.61	30.53
	AUC _{0-inf} (h*ng/mL)	10	160.46	55.21	105.34	159.49	305.43	153.93	29.41
	C _{max} (ng/mL)	10	42.95	12.85	25.21	40.9	70.24	41.31	30.01
	Cl/F(L/h)	10	201.58	50.96	98.22	188.12	284.79	194.9	29.41
	V _d /F(L)	10	1215.59	566.59	704.84	958.75	2271.55	1119.6	42.69
Analyte	Parameter (unit)	N	Mean	SD	CV	Min	Median	Max	
Ketamine	t _{1/2} (h)	10	4.38	2.17	49.69	-	2.58	3.42	8.27
	λ _z (/h)	10	0.188	0.0692	36.7908	-	0.0838	0.2034	0.2692
Analyte	Parameter (unit)	N	Min	Max	Median	Q1	Q3		
Ketamine	T _{max} (h)	10	-	0.453	1.964	0.631	0.463	1.029	-

FIG. 3A

Analyte	Parameter (unit)	Racemic Ketamine 75 mg IN, Day 8							
		N	Mean	SD	Min	Median	Max	Geometric Mean	Geometric CV%
Ketamine	AUC _{0-t} (h*ng/mL)	11	359.21	77.45	268.99	352.21	522.83	352.07	21.03
	AUC _{0-inf} (h*ng/mL)	11	375.98	79.39	289.09	369.17	548.27	368.86	20.46
	C _{max} (ng/mL)	11	101.74	30.33	48.87	97.21	151.79	97.26	33.51
	Cl/F(L/h)	11	207.04	40.21	136.8	203.16	259.44	203.33	20.46
	V _d /F(L)	11	1714.83	457.34	1253.34	1533.67	2616.63	1663.71	25.81
Analyte	Parameter (unit)	N	Mean	SD	CV	Min	Median	Max	
Ketamine	t _{1/2} (h)	11	5.8	1.27	21.86	-	3.35	6.06	8.45
	λ _z /(h)	11	0.1254	0.0318	25.4019	-	0.082	0.1144	0.207
Analyte	Parameter (unit)	N	Min	Max	Median	Q1	Q3		
Ketamine	T _{max} (h)	11	-	0.451	1.966	0.803	0.471	1.034	-

FIG. 3B

Analyte	Parameter (unit)	Racemic Ketamine 90 mg IN, Day 8							
		N	Mean	SD	Min	Median	Max	Geometric Mean	Geometric CV%
Ketamine	AUC ₀₋₁ (h*ng/mL)	12	382.85	94.82	243.04	378.03	594.03	372.38	25.03
	AUC _{0-inf} (h*ng/mL)	12	405.4	105.39	254.58	403.17	657.92	393.65	25.62
	C _{max} (ng/mL)	12	113.22	41.89	51.81	111.42	191.72	105.81	41.04
	Cl/F(L/h)	12	235.32	59.19	136.79	223.26	353.52	228.63	25.62
	V _d /F(L)	12	1890.32	767.91	957.38	1643.55	3374.55	1760.23	40.54
Analyte	Parameter (unit)	N	Mean	SD	CV	Min	Median	Max	
Ketamine	t _{1/2} (h)	12	5.72	2.07	36.2	-	2.68	6.12	8.47
	λ _c (/h)	12	0.1407	0.0621	44.1486	-	0.0819	0.1133	0.259
Analyte	Parameter (unit)	N	Min	Max	Median	Q1	Q3		
Ketamine	T _{max} (h)	12	-	0.457	1.975	0.639	0.477	1.035	-

FIG. 3C

Analyte	Parameter (unit)	Racemic Ketamine 30 mg IN, Day 1							
		N	Mean	SD	Min	Median	Max	Geometric Mean	Geometric CV%
Norketamine	AUC ₀₋₄ (h*ng/mL)	12	430.29	98.68	258.13	444.95	595.1	419.31	24.59
	AUC _{0-inf} (h*ng/mL)	12	481.36	114.82	266.15	479.21	675.33	467.63	26.36
	C _{max} (ng/mL)	12	74.08	21.72	43.45	71.04	109.22	71.16	30.48
Analyte	Parameter (unit)	N	Mean	SD	CV	Min	Median	Max	
Norketamine	t _{1/2} (h)	12	7.68	1.53	19.89	-	5.1	7.66	11.09
	λ _z (/h)	12	0.0937	0.0191	20.3552	-	0.0625	0.0905	0.136
Analyte	Parameter (unit)	N	Mean	SD	CV	Min	Median	Q1	Q3
Norketamine	T _{max} (h)	12	-	1.02	2.968	1.493	1.042	1.758	-

FIG. 4A

Analyte	Parameter (unit)	Racemic Ketamine 75 mg IN, Day 1						
		N	Mean	SD	Min	Median	Max	Geometric Mean Geometric CV%
Norketamine	AUC ₀₋₄ (h*ng/mL)	12	1139.94	271.22	698.77	1075.34	1606.09	1110.26 24.53
	AUC _{0-inf} (h*ng/mL)	12	1279.47	319.04	742.88	1193.89	1874.83	1242.82 25.86
	C _{max} (ng/mL)	12	166.74	40.21	79.02	162.77	236.56	161.49 28.49
Analyte	Parameter (unit)	N	Mean	SD	CV	Min	Median	Max
Norketamine	t _{1/2} (h)	12	7.57	1.16	15.36	-	5.71	7.65 9.17
	λ _z (h)	12	0.0938	0.0155	16.536	-	0.0756	0.0906 0.1214
Analyte	Parameter (unit)	N	Mean	Min	Max	Median	Q1	Q3
Norketamine	T _{max} (h)	12	-	0.821	5.99	2.466	1.955	3.468 -

FIG. 4B

Analyte	Parameter (unit)	Racemic Ketamine 90 mg IN, Day 1							
		N	Mean	SD	Min	Median	Max	Geometric Mean	Geometric CV%
Norketamine	AUC ₀₋₄ (h*ng/mL)	12	1414.51	314.81	899.58	1390.35	2063.12	1382.95	22.54
	AUC _{0-inf} (h*ng/mL)	12	1606.36	411.89	926.51	1611.16	2380.41	1557.04	26.91
	C _{max} (ng/mL)	12	224.61	59.36	149.89	214.18	363.43	218.05	25.49
Analyte	Parameter (unit)	N	Mean	SD	CV	Min	Median	Max	
Norketamine	t _{1/2} (h)	12	7.64	2.16	28.3	-	4.99	7.49	12.42
	λ _z (/h)	12	0.0973	0.0263	27.0644	-	0.0558	0.0925	0.1389
Analyte	Parameter (unit)	N		Min	Max	Median	Q1	Q3	
Norketamine	T _{max} (h)	12	-	0.811	3.982	2.468	1.802	3.465	-

FIG. 4C

Analyte	Parameter (unit)	Racemic Ketamine 30 mg IN, Day 4							
		N	Mean	SD	Min	Median	Max	Geometric Mean	Geometric CV%
Norketamine	AUC ₀₋₄ (h*ng/mL)	11	493	100.82	335.16	470.9	704.27	484	20.25
	AUC _{0-inf} (h*ng/mL)	11	550.6	133.9	345.91	534.33	851.44	536.68	23.93
	C _{max} (ng/mL)	11	78.19	20.2	50.33	77.11	117.48	75.84	26.55
Analyte	Parameter (unit)	N	Mean	SD	CV	Min	Median	Max	
Norketamine	t _{1/2} (h)	11	7.37	1.37	18.6	-	5.1	7.61	9.87
	λ _z (/h)	11	0.0972	0.019	19.5667	-	0.0703	0.0911	0.1358
Analyte	Parameter (unit)	N	Min	Max	Median	Q1	Q3		
Norketamine	T _{max} (h)	11	-	0.799	2.956	1.464	1.054	1.945	-

FIG. 5A

Analyte	Parameter (unit)	Racemic Ketamine 75 mg IN, Day 4							
		N	Mean	SD	Min	Median	Max	Geometric Mean	Geometric CV%
Norketamine	AUC ₀₋₄ (h*ng/mL)	11	1252.32	266.55	813.9	1185.38	1603.73	1225.66	22.31
	AUC _{0-inf} (h*ng/mL)	11	1416.35	306	956.15	1306.91	1801.15	1385.8	22.34
	C _{max} (ng/mL)	11	181.87	50.55	129.13	156.92	275.5	176.23	26.04
Analyte	Parameter (unit)	N	Mean	SD	CV	Min	Median	Max	
Norketamine	t _{1/2} (h)	11	7.82	1.35	17.33	-	5.6	7.6	10.2
	λ _z (h)	11	0.0912	0.0161	17.6688	-	0.068	0.0912	0.1238
Analyte	Parameter (unit)	N	Mean	Min	Max	Median	Q1	Q3	
Norketamine	T _{max} (h)	11	-	1.039	3.974	1.96	1.515	2.959	-

FIG. 5B

Analyte	Parameter (unit)	Racemic Ketamine 90 mg IN, Day 4							
		N	Mean	SD	Min	Median	Max	Geometric Mean	Geometric CV%
Norketamine	AUC ₀₋₄ (h*ng/mL)	12	1432.56	322.05	1105.21	1315.43	2032.22	1402.76	21.14
	AUC _{0-inf} (h*ng/mL)	12	1606.19	398.26	1144.01	1477.93	2358.23	1565.09	23.64
	C _{max} (ng/mL)	12	223.53	51.72	153.62	210.52	328.86	218.35	22.68
Analyte	Parameter (unit)	N	Mean	SD	CV	Min	Median	Max	
Norketamine	t _{1/2} (h)	12	7.38	1.6	21.63	-	4.99	7.51	9.77
	λ _c (/h)	12	0.0984	0.0231	23.4925	-	0.0709	0.0924	0.139
Analyte	Parameter (unit)	N	Mean	Min	Max	Median	Q1	Q3	
Norketamine	T _{max} (h)	12	-	1.496	3.985	1.948	1.518	2.955	-

FIG. 5C

Analyte	Parameter (unit)	Racemic Ketamine 30 mg IN, Day 8							
		N	Mean	SD	Min	Median	Max	Geometric Mean	Geometric CV%
Norketamine	AUC _{0-t} (h*ng/mL)	10	540.73	63.79	447.13	529.59	640.84	537.36	11.83
	AUC _{0-inf} (h*ng/mL)	10	604.42	75.97	501.94	589.1	730.21	600.16	12.57
	C _{max} (ng/mL)	10	84.23	22.63	60.95	78.1	130.58	81.77	25.55
Analyte	Parameter (unit)	N	Mean	SD	CV	Min	Median	Max	
Norketamine	t _{1/2} (h)	10	7.62	0.98	12.9	-	5.67	7.67	8.79
	λ _z (/h)	10	0.0925	0.0134	14.4624	-	0.0789	0.0903	0.1223
Analyte	Parameter (unit)	N	Min	Max	Median	Q1	Q3		
Norketamine	T _{max} (h)	10	-	0.77	2.948	1.277	0.995	1.964	-

FIG. 6A

Analyte	Parameter (unit)	Racemic Ketamine 75 mg IN, Day 8							
		N	Mean	SD	Min	Median	Max	Geometric Mean	Geometric CV%
Norketamine	AUC ₀₋₄ (h*ng/mL)	11	1353.04	296.74	837.89	1464.65	1762.41	1321.13	23.78
	AUC _{0-inf} (h*ng/mL)	11	1543	337.72	967.79	1556.23	2049.78	1507.97	23.13
	C _{max} (ng/mL)	11	195.99	38.55	124.6	201	250.66	192.22	21.48
Analyte	Parameter (unit)	N	Mean	SD	CV	Min	Max	Median	Max
Norketamine	t _{1/2} (h)	11	7.63	1.46	19.18	-	5.27	7.65	9.86
	λ _z (/h)	11	0.0942	0.02	21.2093	-	0.0703	0.0906	0.1316
Analyte	Parameter (unit)	N	Min	Max	Median	Q1	Q3		
Norketamine	T _{max} (h)	11	-	1.126	2.966	1.954	1.534	1.967	-

FIG. 6B

Analyte	Parameter (unit)	Racemic Ketamine 90 mg IN, Day 8							
		N	Mean	SD	Min	Median	Max	Geometric Mean	Geometric CV%
Norketamine	AUC ₀₋₄ (h*ng/mL)	12	1525.79	321.87	1148.56	1465.32	2159.52	1497.08	20.24
	AUC _{0-inf} (h*ng/mL)	12	1741.54	411.15	1185.03	1707.91	2466.86	1698.69	23.55
	C _{max} (ng/mL)	12	226.67	47.57	165.98	215.83	332.19	222.39	20.35
Analyte	Parameter (unit)	N	Mean	SD	CV	Min	Median	Max	
Norketamine	t _{1/2} (h)	12	7.46	1.81	24.3	-	5.03	7.66	11.13
	λ _z (/h)	12	0.098	0.0236	24.1146	-	0.0623	0.0908	0.1379
Analyte	Parameter (unit)	N	Mean	Min	Max	Median	Q1	Q3	
Norketamine	T _{max} (h)	12	-	0.833	3.984	1.543	1.514	2.473	-

FIG. 6C

Analyte	Parameter (unit)	Racemic Ketamine 30 mg IN, Day 1							
		N	Mean	SD	Min	Median	Max	Geometric Mean	Geometric CV%
Hydroxynorketamine	AUC ₀₋₄ (h*ng/mL)	12	530.42	131.13	301.86	513.65	771.9	514.82	26.5
	AUC _{0-inf} (h*ng/mL)	12	689.17	196.21	405.08	673.9	1066.8	663.59	29.63
	C _{max} (ng/mL)	12	41.81	12.92	19.89	40.73	71.91	40.02	32.17
Analyte	Parameter (unit)	N	Mean	SD	CV	Median	Min	Median	Max
Hydroxynorketamine	t _{1/2} (h)	12	10.67	2.19	20.49	-	5.93	11.46	13.24
	λ _z (h)	12	0.0684	0.0188	27.5138	-	0.0524	0.0605	0.1169
Analyte	Parameter (unit)	N	Mean	SD	CV	Median	Q1	Q3	
Hydroxynorketamine	T _{max} (h)	12	-	1.961	4	2.973	1.981	3.969	-

FIG. 7A

Analyte	Parameter (unit)	Racemic Ketamine 75 mg IN, Day 1							
		N	Mean	SD	Min	Median	Max	Geometric Mean	Geometric CV%
Hydroxynorketamine	AUC ₀₋₄ (h*ng/mL)	12	1240.73	316.14	833.31	1207.45	1665.37	1202.77	26.79
	AUC _{0-inf} (h*ng/mL)	12	1682	445.65	1105.86	1724	2362.18	1626.96	27.68
	C _{max} (ng/mL)	12	89.36	28.07	52.79	83.71	145.3	85.44	32.09
Analyte	Parameter (unit)	N	Mean	SD	CV	Min	Median	Max	
Hydroxynorketamine	t _{1/2} (h)	12	11.44	2.58	22.57	-	8.56	10.67	17.92
	λ _z (/h)	12	0.063	0.0123	19.5036	-	0.0387	0.065	0.081
Analyte	Parameter (unit)	N	Min	Max	Median	Q1	Q3		
Hydroxynorketamine	T _{max} (h)	12	-	2.946	7.982	3.971	2.998	5.99	-

FIG. 7B

Racemic Ketamine 90 mg IN, Day 1									
Analyte	Parameter (unit)	N	Mean	SD	Min	Median	Max	Geometric Mean	Geometric CV%
Hydroxynorketamine	AUC _{0-t} (h*ng/mL)	12	1978.45	471.48	1331.48	1831.16	2842.61	1929.66	23.46
	AUC _{0-inf} (h*ng/mL)	12	2628.39	580.6	1815.8	2715.17	3668.03	2569.54	22.62
	C _{max} (ng/mL)	12	151.87	48.76	76.55	140.1	233.13	144.7	33.78
Analyte	Parameter (unit)	N	Mean	SD	CV	Min	Median	Max	
Hydroxynorketamine	t _{1/2} (h)	12	11.05	3.15	28.51	-	6.91	9.91	15.7
	λ _z (/h)	12	0.0673	0.0181	26.8883	-	0.0441	0.07	0.1003
Analyte	Parameter (unit)	N	Min	Max	Median	Q1	Q3		
Hydroxynorketamine	T _{max} (h)	12	-	0.811	7.973	3.956	2.962	4.98	-

FIG. 7C

Analyte	Parameter (unit)	Racemic Ketamine 30 mg IN, Day 4							
		N	Mean	SD	Min	Median	Max	Geometric Mean	Geometric CV%
Hydroxynorketamine	AUC _{0-t} (h*ng/mL)	11	524.62	165.38	311.65	474.82	778.65	501.56	32.25
	AUC _{0-inf} (h*ng/mL)	11	704.71	242.31	398.88	702.53	1149.11	667.11	36.19
	C _{max} (ng/mL)	11	40.72	17.23	22.48	34.96	81.58	37.97	39.4
Hydroxynorketamine	Parameter (unit)	N	Mean	SD	CV	Min	Median	Max	
	t _{1/2} (h)	11	11.44	2.74	23.94	-	6.33	11.12	14.99
	λ _z (/h)	11	0.0645	0.019	29.4037	-	0.0463	0.0623	0.1095
Hydroxynorketamine	Parameter (unit)	N	Min	Max	Median	Q1	Q3		
	T _{max} (h)	11	-	1.551	3.99	2.959	2.947	3.964	-

FIG. 8A

Analyte	Parameter (unit)	Racemic Ketamine 75 mg IN, Day 4							
		N	Mean	SD	Min	Median	Max	Geometric Mean	Geometric CV%
Hydroxynorketamine	AUC ₀₋₄ (h*ng/mL)	11	1314.05	268.67	942.32	1369.35	1684.18	1287.63	21.75
	AUC _{0-inf} (h*ng/mL)	11	1814.08	338.04	1299.52	1746.14	2349.09	1784.92	19.21
	C _{max} (ng/mL)	11	95.68	24.89	54.42	96.43	132.02	92.47	28.77
Analyte	Parameter (unit)	N	Mean	SD	CV	Min	Median	Max	
Hydroxynorketamine	t _{1/2} (h)	11	12.24	3.67	29.95	-	8.35	11.44	22.26
	λ _c (/h)	11	0.06	0.0132	21.9713	-	0.0311	0.0606	0.083
Analyte	Parameter (unit)	N		Min	Max	Median	Q1	Q3	
Hydroxynorketamine	T _{max} (h)	11	-	2.946	5.982	3.945	2.947	3.971	-

FIG. 8B

Analyte	Parameter (unit)	Racemic Ketamine 90 mg IN, Day 4							
		N	Mean	SD	Min	Median	Max	Geometric Mean	Geometric CV%
Hydroxynorketamine	AUC ₀₋₄ (h*ng/mL)	12	1947.96	532.94	1188.89	1886.4	3033.65	1883.73	27.49
	AUC _{0-inf} (h*ng/mL)	12	2545.05	641.47	1770.61	2340.73	3668.86	2473.23	25.29
	C _{max} (ng/mL)	12	154.08	54.71	71.73	149.58	254.76	145	38.45
Analyte	Parameter (unit)	N	Mean	SD	CV	Min	Median	Max	
Hydroxynorketamine	t _{1/2} (h)	12	10.78	2.64	24.5	-	7.84	10.21	15.17
	λ _z (/h)	12	0.0677	0.0155	22.8751	-	0.0457	0.068	0.0884
Analyte	Parameter (unit)	N	Min	Max	Median	Q1	Q3		
Hydroxynorketamine	T _{max} (h)	12	-	2.941	5.978	3.953	2.971	3.983	-

FIG. 8C

Analyte	Parameter (unit)	Racemic Ketamine 30 mg IN, Day 8							
		N	Mean	SD	Min	Median	Max	Geometric Mean	Geometric CV%
Hydroxynorketamine	AUC _{0-t} (h*ng/mL)	10	497.63	174.77	305.35	468.96	806.33	472.1	34.85
	AUC _{0-inf} (h*ng/mL)	10	669.74	244.12	378.23	679.66	1075.82	629.81	38.67
	C _{max} (ng/mL)	10	36.51	11.6	22.43	34.85	57.25	34.98	31.23
Analyte	Parameter (unit)	N	Mean	SD	CV	Min	Median	Max	
Hydroxynorketamine	t _{1/2} (h)	10	11.41	2.4	21.06	-	8.23	11	16.6
	λ _z (/h)	10	0.063	0.0123	19.4417	-	0.0417	0.0631	0.0842
Analyte	Parameter (unit)	N	Min	Max	Median	Q1	Q3		
Hydroxynorketamine	T _{max} (h)	10	-	1.023	4.049	3.95	2.95	3.959	-

FIG. 9A

Racemic Ketamine 75 mg IN, Day 8									
Analyte	Parameter (unit)	N	Mean	SD	Min	Median	Max	Geometric Mean	Geometric CV%
Hydroxynorketamine	AUC ₀₋₄ (h*ng/mL)	11	1264.63	338.58	663.15	1278.43	1853.57	1219.24	30
	AUC _{0-inf} (h*ng/mL)	11	1767.83	354.53	1192.95	1894.53	2305.7	1733.57	21.36
	C _{max} (ng/mL)	11	94.11	23.15	57.91	91.2	133.99	91.4	26.28
Analyte	Parameter (unit)	N	Mean	SD	CV	Min	Median	Max	
Hydroxynorketamine	t _{1/2} (h)	11	11.95	3.4	28.43	-	9.13	11.23	20.51
	λ _z (/h)	11	0.0613	0.0133	21.6639	-	0.0338	0.0617	0.0759
Analyte	Parameter (unit)	N	Min	Max	Median	Q1	Q3		
Hydroxynorketamine	T _{max} (h)	11	-	1.963	3.975	2.966	2.951	3.971	-

FIG. 9B

Analyte	Parameter (unit)	Racemic Ketamine 90 mg IN, Day 8							
		N	Mean	SD	Min	Median	Max	Geometric Mean	Geometric CV%
Hydroxy norketamine	AUC ₀₋₄ (h*ng/mL)	12	1868.21	384.62	1084.85	1882.49	2478.69	1828.12	22.75
	AUC _{0-inf} (h*ng/mL)	12	2432.59	492.85	1694.08	2446.31	3247.7	2386.27	20.84
	C _{max} (ng/mL)	12	153.28	52.99	66.69	154.48	248.77	144.17	39.29
Analyte	Parameter (unit)	N	Mean	SD	CV	Min	Median	Max	
Hydroxy norketamine	t _{1/2} (h)	12	10.03	2.79	27.78	-	6.42	9.48	15.55
	λ _z (/h)	12	0.0738	0.0191	25.8744	-	0.0446	0.0732	0.108
Analyte	Parameter (unit)	N	Min	Max	Median	Q1	Q3		
Hydroxy norketamine	T _{max} (h)	12	-	1.948	5.991	3.956	3.451	3.989	-

FIG. 9C

DAY 1	Racemic Ketamine 60 mg IN + placebo IV					Ketamine IV 0.3 mg/kg (dose equivalent to 60 mg IN) + placebo IN				
Parameter (unit)	N	Geometric Mean	SD	Min	Max	N	Geometric Mean	SD	Min	Max
AUC ₀₋₄ (h*ng/mL)	12	271.15	91.91	127.92	449.82	12	319.48	43.91	244.99	371.32
AUC _{0-inf} (h*ng/mL)	12	284.96	93.6	142.56	468.36	12	334.89	46.32	257.56	400.9
C _{max} (ng/mL)	12	69.02	23.8	49.78	127.1	12	134.31	35.91	93.99	206.84
Cl/F (L/h)	12	210.55	78.02	128.11	420.87	12	71.51	11.49	55.15	89.11
V _d /F (L)	12	1415.11	430.47	832.66	2208.16	12	509.68	158.17	257.19	802.41
F _{abs} (%)	12	33.96	8	18.9	46.02		-	-	-	-
	N	Mean	SD	Min	Max	N	Mean	SD	Min	Max
t _{1/2} (h)	12	4.84	1.29	2.59	6.49	12	5.2	1.61	2.56	8.02
λ _z (h)	12	0.1559	0.0541	0.1069	0.2676	12	0.1489	0.0577	0.0864	0.2707
	N	Median	Min	Max		N	Median	Min	Max	
T _{max} (h)	12	0.679	0.361	1.544	-	12	0.254	0.126	0.378	-

FIG. 10A

DAY 4	Racemic Ketamine 60 mg IN + placebo IV					Ketamine IV 0.3 mg/kg (dose equivalent to 60 mg IN) + placebo IN				
Parameter (unit)	N	Geometric Mean	SD	Min	Max	N	Geometric Mean	SD	Min	Max
AUC ₀₋₁ (h*ng/mL)	11	279.04	64.7	196.13	397.24	12	302.49	49.39	209.02	392.31
AUC _{0-inf} (h*ng/mL)	11	292.39	65.72	205.25	407.95	12	316.69	51.96	219.78	406.95
C _{max} (ng/mL)	11	74.68	14.46	56.59	99.79	12	107.22	33.77	68.31	184.73
Cl/F (L/h)	11	205.21	47.31	147.08	292.33	12	75.62	11.64	56.47	104.42
V _d /F (L)	11	1445.64	556.74	837.58	2587.67	12	522.82	155.92	279.97	751.74
F _{abs} (%)	12	36.77	6.4	28.56	52.97		-	-	-	-
Parameter (unit)	N	Mean	SD	Min	Max	N	Mean	SD	Min	Max
t _{1/2} (h)	11	5.08	1.35	2.62	6.33	12	5.06	1.57	2.49	7.11
λz(/h)	11	0.1491	0.0538	0.1095	0.2647	12	0.1546	0.0639	0.0974	0.2783
Parameter (unit)	N	Median	Min	Max		N	Median	Min	Max	
T _{max} (h)	11	0.674	0.593	0.732	-	12	0.358	0.124	0.371	-

FIG. 10B

DAY 8	Racemic Ketamine 60 mg IN + placebo IV					Ketamine IV 0.3 mg/kg (dose equivalent to 60 mg IN) + placebo IN				
Parameter (unit)	N	Geometric Mean	SD	Min	Max	N	Geometric Mean	SD	Min	Max
AUC ₀₋₄ (h*ng/mL)	11	280.19	64.54	184.63	410.68	12	312.53	41.23	242.05	369.73
AUC _{0-inf} (h*ng/mL)	11	293.55	64.6	192.54	419.61	12	328.98	43.99	255.79	387.23
C _{max} (ng/mL)	11	68.73	16	50.27	93.69	12	112.8	28.97	63.49	157.08
Cl/F (L/h)	11	204.39	49.55	142.99	311.63	12	72.79	11.09	55.63	89.72
V _d /F (L)	11	1443.57	497.26	777.08	2463.35	12	491.55	197.42	218.76	804.96
F _{abs} (%)	11	35.4	4.81	25.6	42.05		-	-	-	-
	N	Mean	SD	Min	Max	N	Mean	SD	Min	Max
t _{1/2} (h)	11	5.05	1.24	2.74	6.79	12	5	1.74	2.69	7.32
λ _z (/h)	11	0.147	0.0457	0.1022	0.253	12	0.1596	0.0669	0.0947	0.2577
	N	Median	Min	Max		N	Median	Min	Max	
T _{max} (h)	11	0.68	0.364	1.561	-	12	0.145	0.12	0.364	-

FIG. 10C

DAY 1	Racemic Ketamine 60 mg IN + placebo IV Analyte: Norketamine					Ketamine IV 0.3 mg/kg (dose equivalent to 60 mg IN) + placebo IN Analyte: Norketamine				
Parameter (unit)	N	Geometric Mean	SD	Min	Max	N	Geometric Mean	SD	Min	Max
AUC _{0-t} (h*ng/mL)	12	916.10	324.6	512.57	1387.63	12	450.56	120.69	260.24	669.09
AUC _{0-inf} (h*ng/mL)	12	1016.76	356.96	571.31	1568.07	12	527.63	165.05	278.20	819.97
C _{max} (ng/mL)	12	127.26	39.28	77.45	200.80	12	48.85	11.53	33.71	70.09
F _{abs} (%)	12	76.91	15.08	54.06	105.17	-	-	-	-	-
	N	Mean	SD	Min	Max	N	Mean	SD	Min	Max
t _{1/2} (h)	12	6.80	0.97	5.30	7.88	12	8.48	1.71	6.01	11.32
λ _z (/h)	12	0.1042	0.0166	0.0879	0.1309	12	0.0851	0.0182	0.0613	0.1153
	N	Median	Min	Max		N	Median	Min	Max	
T _{max} (h)	12	1.560	1.509	2.841	-	12	1.510	0.609	2.853	-

FIG. 11A

DAY 4	Racemic Ketamine 60 mg IN + placebo IV Analyte: Norketamine					Ketamine IV 0.3 mg/kg (dose equivalent to 60 mg IN) + placebo IN Analyte: Norketamine				
Parameter (unit)	N	Geometric Mean	SD	Min	Max	N	Geometric Mean	SD	Min	Max
AUC ₀₋₄ (h*ng/mL)	11	1044.26	252.75	744.00	1601.85	12	472.00	115.66	255.75	678.76
AUC _{0-inf} (h*ng/mL)	11	1165.75	284.80	804.87	1769.65	12	568.49	154.71	275.01	832.04
C _{max} (ng/mL)	11	144.52	30.80	114.49	228.13	12	46.50	16.44	26.51	83.01
F _{abs} (%)	11	84.07	12.64	67.21	111.94	-	-	-	-	-
	N	Mean	SD	Min	Max	N	Mean	SD	Min	Max
t _{1/2} (h)	11	7.13	0.96	5.54	8.18	12	9.19	2.01	6.07	12.51
λ _z (h)	11	0.0989	0.0145	0.0847	0.1252	12	0.0792	0.0192	0.0554	0.1142
	N	Median	Min	Max		N	Median	Min	Max	
T _{max} (h)	11	1.548	0.696	3.936	-	12	1.110	0.603	2.856	-

FIG. 11B

DAY 8	Racemic Ketamine 60 mg IN + placebo IV Analyte: Norketamine					Ketamine IV 0.3 mg/kg (dose equivalent to 60 mg IN) + placebo IN Analyte: Norketamine				
Parameter (unit)	N	Geometric Mean	SD	Min	Max	N	Geometric Mean	SD	Min	Max
AUC ₀₋₄ (h*ng/mL)	11	1048.16	305.24	605.48	1595.10	12	520.04	104.28	327.28	690.36
AUC _{0-inf} (h*ng/mL)	11	1173.89	334.12	688.74	1769.16	12	632.68	139.02	352.78	887.65
C _{max} (ng/mL)	11	141.00	23.96	94.57	186.75	12	47.43	9.52	35.30	64.51
F _{abs} (%)	11	75.17	9.92	63.38	88.63	-	-	-	-	-
	N	Mean	SD	Min	Max	N	Mean	SD	Min	Max
t _{1/2} (h)	11	7.20	0.90	5.75	8.40	12	9.49	2.37	6.27	14.11
λ _z (h)	11	0.0977	0.0127	0.0825	0.1206	12	0.0774	0.0198	0.0491	0.1106
	N	Median	Min	Max		N	Median	Min	Max	
T _{max} (h)	11	1.538	0.707	2.860	-	12	1.119	0.593	2.848	-

FIG. 11C

DAY 1	Racemic Ketamine 60 mg IN + placebo IV Analyte: Hydroxynorketamine					Ketamine IV 0.3 mg/kg (dose equivalent to 60 mg IN) + placebo IN Analyte: Hydroxynorketamine				
Parameter (unit)	N	Geometric Mean	SD	Min	Max	N	Geometric Mean	SD	Min	Max
AUC ₀₋₄ (h*ng/mL)	12	894.11	205.64	708.00	1358.57	12	424.24	96.50	278.03	600.00
AUC _{0-inf} (h*ng/mL)	12	1182.22	270.01	877.97	1693.91	12	627.53	153.65	405.56	945.67
C _{max} (ng/mL)	12	66.39	17.58	46.58	102.91	12	25.57	7.47	15.91	40.41
F _{abs} (%)	12	75.19	17.17	49.24	107.72	-	-	-	-	-
	N	Mean	SD	Min	Max	N	Mean	SD	Min	Max
t _{1/2} (h)	12	10.94	2.20	8.17	16.13	12	13.85	3.54	9.27	21.04
λ _z (/h)	12	0.0655	0.0118	0.0430	0.0848	12	0.0529	0.0124	0.0329	0.0748
	N	Median	Min	Max		N	Median	Min	Max	
T _{max} (h)	12	3.902	1.509	8.028	-	12	3.927	2.817	7.945	-

FIG. 12A

DAY 4	Racemic Ketamine 60 mg IN + placebo IV Analyte: Hydroxynorketamine	Ketamine IV 0.3 mg/kg (dose equivalent to 60 mg IN) + placebo IN Analyte: Hydroxynorketamine				
Parameter (unit)	N	Geometric Mean	SD	Min	Max	
AUC ₀₋₄ (h*ng/mL)	11	940.26	233.03	698.54	1485.54	623.66
AUC _{0-inf} (h*ng/mL)	11	1303.53	308.68	941.36	2082.75	1045.14
C _{max} (ng/mL)	11	66.90	20.83	41.97	116.18	35.40
F _{abs} (%)	11	74.57	9.57	60.41	92.00	-
	N	Mean	SD	Min	Max	Max
t _{1/2} (h)	11	12.20	2.08	9.21	15.94	23.32
λ _z (/h)	11	0.0584	0.0100	0.0435	0.0753	0.0727
	N	Median	Min	Max		
T _{max} (h)	11	3.911	1.523	3.936	-	-

FIG. 12B

DAY 8	Racemic Ketamine 60 mg IN + placebo IV Analyte: Hydroxynorketamine					Ketamine IV 0.3 mg/kg (dose equivalent to 60 mg IN) + placebo IN Analyte: Hydroxynorketamine				
Parameter (unit)	N	Geometric Mean	SD	Min	Max	N	Geometric Mean	SD	Min	Max
AUC ₀₋₄ (h*ng/mL)	11	885.67	191.68	647.79	1236.82	12	414.61	75.15	281.39	509.22
AUC _{0-inf} (h*ng/mL)	11	1239.35	268.20	831.38	1757.25	12	661.42	144.50	438.67	1027.38
C _{max} (ng/mL)	11	64.07	18.60	43.56	107.74	12	25.39	6.61	16.34	35.89
F _{abs} (%)	11	73.01	10.13	61.05	89.18	-	-	-	-	-
	N	Mean	SD	Min	Max	N	Mean	SD	Min	Max
t _{1/2} (h)	11	12.54	2.05	10.09	16.56	12	15.8	3.77	10.96	22.80
λ _z (h)	11	0.0565	0.0086	0.0419	0.0687	12	0.0462	0.0107	0.0304	0.0633
	N	Median	Min	Max		N	Median	Min	Max	
T _{max} (h)	11	3.92	2.845	3.949	-	12	3.927	2.831	8.026	-

FIG. 12C

Montgomery-Asberg Depression Rating Scale (MADRS) Total Score (Range 0 – 60)											
	Day 1			24 Hours (Day 2)	Day 3	Day 4*	Day 5	Day 6	Day 7	Day 8*	Day 9
	Baseline*	4 Hrs									
Subject 1	35	18	8 ^{1,2}	12 ^{1,2}	9 ^{1,2}	2 ^{1,2}	2 ^{1,2}	2 ^{1,2}	na	7 ^{1,2}	na
Subject 2	38	35	15 ²	7 ^{1,2}	13 ²	10 ^{1,2}	11 ^{1,2}	11 ^{1,2}	na	16 ²	na
Mean	36.5	26.5	11.5 ^{1,2}	9.5 ^{1,2}	11.0 ^{1,2}	6.0 ^{1,2}	6.5 ^{1,2}	6.5 ^{1,2}	na	11.5 ^{1,2}	na
* Dosing Day											
¹ Meets Definition of MADRS Remission; MADRS Total ≤ 12											
² Meets Definition of MADRS Response; MADRS Total ≤ 50% of Baseline											
na = not applicable											

FIG. 13A




FIG. 13B

Clinical Global Impression of Severity for Suicide Ideation and Behavior (CGIS-SI/B) (Range 1 – 5)											
	Day 1		24 Hours (Day 2)	4 Hrs	Day 3	Day 4*	Day 5	Day 6	Day 7	Day 8*	Day 9
	Baseline*										
Subject 1	4	1	1		1	1	1	1	1	1	1
Subject 2	4	4	2		1	1	1	1	1	1	1
Mean	4.0	2.5	1.5		1.0	1.0	1.0	1.0	1.0	1.0	1.0
* Dosing Day											
Scores range from 1 = Not At All Suicidal to 5 = Among The Most Extremely Suicidal											

FIG. 14A




FIG. 14B

Sheehan – Suicidality Tracking Scale (S-STs) Clinically Meaningful Change Measure (CMCM) (Range 0 – 52)										
	Day 1		24 Hours (Day 2)	Day 3	Day 4*	Day 5	Day 6	Day 7	Day 8*	Day 9
	Baseline*	4 Hrs								
Subject 1	18	0	0	0	0	0	0	0	0	0
Subject 2	22	18	3	0	0	0	0	0	0	0
Mean	20.0	9.0	1.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0
* Dosing Day										

FIG. 15A




FIG. 15B

Patient Global Impression of Severity for Suicide Ideation and Behavior (PGIS-SI/B) (Range 1 – 5)										
	Day 1		24 Hours (Day 2)	Day 3	Day 4*	Day 5	Day 6	Day 7	Day 8*	Day 9
	Baseline*	4 Hrs								
Subject 1	3	2	1	1	1	1	1	1	1	1
Subject 2	4	4	1	1	1	1	1	1	1	1
Mean	3.5	3.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0
* Dosing Day Scores range from 1 = Not Present to 5 = Extremely Severe										

FIG. 16A




FIG. 16B

Clinical Global Impression of Change in Suicide Ideation and Behavior (CGIC-SI/B) (Range 1 – 7)										
	Day 1		24 Hours (Day 2)	Day 3	Day 4*	Day 5	Day 6	Day 7	Day 8*	Day 9
	Baseline*	4 Hrs								
Subject 1	na	1	1	1	1	1	1	1	na	na
Subject 2	na	na	1	1	1	1	1	1	1	na
Mean	na	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	na
* Dosing Day Scores range from 1 = Very Much Improved to 7 = Very Much Worse na = not applicable										

FIG. 17

Patient Global Impression of Change in Suicide Ideation and Behavior (PGIC-SI/B) (Range 1 – 5)										
	Day 1		24 Hours (Day 2)	Day 3	Day 4*	Day 5	Day 6	Day 7	Day 8*	Day 9
	Baseline*	4 Hrs								
Subject 1	na	2	1	1	1	1	1	1	1	1
Subject 2	na	3	2	1	2	1	1	1	1	1
Mean	na	2.5	1.5	1.0	1.5	1.0	1.0	1.0	1.0	1.0
* Dosing Day Scores range from 1= Very Much Improved to 7 = Very Much Worse na = not applicable										

FIG. 18

Montgomery-Asberg Depression Rating Scale (MADRS)										
Item 10 Score (Range 0 – 6)										
	Day 1		24 Hours (Day 2)	Day 3	Day 4*	Day 5	Day 6	Day 7	Day 8*	Day 9
	Baseline*	4 Hrs								
Subject 1	5	1	0 ³	0 ³	0 ³	0 ³	0 ³	na	0 ³	na
Subject 2	5	4	0 ³	0 ³	0 ³	0 ³	0 ³	na	0 ³	na
Mean	5.0	2.5 ³	0.0 ³	0.0 ³	0.0 ³	0.0 ³	0.0 ³	na	0.0 ³	na
* Dosing Day										
3 Meets definition of MADRS Item 10 Response; score < 3										
na = not applicable										

FIG. 19A




FIG. 19B

Sheehan – Suicidality Tracking Scale (S-STs) Clinically Meaningful Change Measure (CMCM) Risk of Suicide at This Time (Range 0 – 9)												
	Day 1			24 Hours (Day 2)	4 Hrs	Day 3	Day 4*	Day 5	Day 6	Day 7	Day 8*	Day 9
	Baseline*											
Subject 1	7		3	5	3	3	3	4	2	1	2	2
Subject 2	7		3	7	3	2	1	1	1	2	2	0
Mean	7.0		3.0	6.0	2.5	2.0	2.0	2.5	1.5	1.5	2.0	1.0
* Dosing Day Scores range from 0 = No Apparent Risk to 10 = Severe												

FIG. 20A




FIG. 20B

Sheehan – Suicidality Tracking Scale (S-STS) Clinically Meaningful Change Measure (CMCM) Risk of Suicide at Within the Next 7 Days (Range 1 - 10)										
	Day 1									
	Baseline*	4 Hrs	24 Hours (Day 2)	Day 3	Day 4*	Day 5	Day 6	Day 7	Day 8*	Day 9
Subject 1	5	4	2	0	1	1	1	0	0	0
Subject 2	7	6	1	0	1	0	0	0	0	0
Mean	6.0	5.0	1.5	0.0	1.0	0.5	0.5	0.0	0.0	0.0
* Dosing Day Scores range from 1 = None Apparent to 10 = Extreme										

FIG. 21A




FIG. 21B

Modified Observer's Assessment of Alertness/Sedation (MOAA/s) (Range 0 – 5)												
		Time Relative to Dosing										
Subject	Day	PreDose	15 min	30 min	45 min	60 min	75 min	90 min	2 hours	4 hours	6 hours	24 hours
1	1	5	4	5	5	5	5	5	5	5	5	5
	4	5	5	5	5	5	5	5	5	5	5	na
	8	5	5	5	5	5	5	5	5	5	na	na
2	1	5	5	5	5	5	5	5	5	5	5	5
	4	5	5	5	5	5	5	5	5	5	5	na
	8	5	5	5	5	5	5	5	5	5	na	na
Scores range from 0 = Does Not Respond to Noxious Stimulant to 5 = Responds Readily To Name Spoken In Normal Tone na = not applicable												

FIG. 22

Clinician Administered Dissociative States Scale (CADSS) (Range 0 – 92)									
		Time Relative to Dosing							
Subject	Day	Predose	40 min	1 hour	2 hours	4 hours	6 hours	24 hours	
1	1	0	0	0	0	--	0	0	0
	4	0	0	0	0	0	0	na	na
	8	0	0	0	0	0	na	na	na
2	1	0	3	0	0	0	0	0	0
	4	0	2	0	0	0	0	0	Na
	8	0	0	0	0	0	na	na	na
Scores based on 23 questions for which response ranges from 0 = Not at All to 4 = Extreme na = not applicable									

FIG. 23

Columbia Suicide Severity Rating Scale (C-SSRS)		
Subject	Day	Suicidal Ideation
1	Baseline	YES for 'Wish to be dead'
		YES for 'Non-specific active suicidal thoughts
	24 Hours (Day 2)	NO for all responses
	3	NO for all responses
	4	NO for all responses
	5	NO for all responses
	6	NO for all responses
	7	NO for all responses
	8	NO for all responses
	9	NO for all responses
2	Baseline	YES for 'Wish to be dead'
		YES for 'Non-specific active suicidal thoughts
	24 Hours (Day 2)	YES for 'Wish to be dead'
		NO for 'Non-specific active suicidal thoughts
	3	NO for all responses
	4	NO for all responses
	5	NO for all responses
	6	NO for all responses
	7	NO for all responses
	8	NO for all responses
	9	NO for all responses
FIG. 24		
Suicidal Behavior		
NO for all responses		
NO for all responses		
NO for all responses		
NO for all responses		
NO for all responses		
NO for all responses		
NO for all responses		
NO for all responses		
NO for all responses		